OCM
INDV icon

Oaktree Capital Management’s Indivior Pharmaceuticals INDV Stock Holding History

Oaktree Capital Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$213M Sell
6,984,102
-124,542
-2% -$4.11M 3.25% 6
2025
Q4 		$255M Sell
7,108,644
-250,676,754
-97% -$7.65B 3.63% 7
2025
Q3 		$10.7M Buy
257,785,398
+246,776,273
+2,242% +$5.16B 0.16% 92
2025
Q2 		$162M Hold
11,009,125
– – 2.79% 7
2025
Q1 		$103M Buy
11,009,125
+2,275,577
+26% +$23.9M 2% 9
2024
Q4 		$112M Sell
8,733,548
-788,432
-8% -$8.11M 1.99% 11
2024
Q3 		$94.1M Buy
9,521,980
+5,028,807
+112% +$58.9M 1.51% 18
2024
Q2 		$70.4M Buy
4,493,173
+1,141,937
+34% +$20.6M 1.12% 18
2024
Q1 		$71.7M Buy
+3,351,236
New +$63M 1.13% 19

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Oaktree Capital Management's INDV Position: Q1 2026 in Review

Oaktree Capital Management reduced its Indivior Pharmaceuticals (INDV) stake by 1.8% in Q1 2026, selling an estimated $4.11M and leaving 6,984,102 shares worth $213M. The position accounts for 3.25% of the portfolio, ranked #6.

Oaktree Capital Management first reported a position in INDV in Q1 2024 and has held it in 9 quarters since. The position peaked at $255M in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Oaktree Capital Management held 6,984,102 shares of Indivior Pharmaceuticals worth $213M as of Q1 2026.
  • Oaktree Capital Management sold 124,542 Indivior Pharmaceuticals shares in Q1 2026, an estimated $4.11M.
  • Indivior Pharmaceuticals made up 3.25% of Oaktree Capital Management's portfolio in Q1 2026, its #6 holding.
  • Oaktree Capital Management first reported a position in Indivior Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • Oaktree Capital Management's Indivior Pharmaceuticals position peaked at $255M in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Oaktree Capital Management's 13F filing for Q1 2026, filed 15 May 2026.